Clinical correlation between myeloperoxidase and acute coronary syndrome  

作　　者：Jie Wang Yanwei Xing Changsheng Ma Shihong Li Zhizhong Li Yonghong Gao Yibing Nong 

机构地区：[1]Guanganmen Hospital Chinese Academy of Traditionel Chinese Medical Beijing 100053, China Guanganmen Hospital Chinese Academy of Traditionel Chinese Medical Beijing 100053, China Anzhen Hospital Capital University of Medical Sciences, Beijing 100029, China Anzhen Hospital Capital University of Medical Sciences, Beijing 100029, China Anzhen Hospital Capital University of Medical Sciences, Beijing 100029, China Dongzhimen Hospital Beijing 100700, China Dongfang Hospital Beijing 100701, China

出　　处：《Journal of Geriatric Cardiology》2007年第4期209-212,共4页老年心脏病学杂志（英文版）

摘　　要：Objective To study whether myeloperoxidase (MPO) can provide prognostic information in patients with acute coronary syndromes (ACS). Methods The study population consisted of 274 consecutive patients with ACS. All patients underwent coronary angiography which showed significant coronary artery disease and blood samples were collected at admission. Follow-ups were scheduled at 1, 3, and 6 months.The end point included cardiac death, acute myocardial infarction (MI), percutaneous or surgical revascularization. Results Patients with elevated MPO serum levels (MPO ≥ 72.2 AUU/L) were more likely to have diabetics and had a history of coronary events. Kaplan-Meier event rate curves with accumulative incidence of end point at 6-month follow-up in the MPO ≥ 72.2 AUU/L group was significantly higher than in MPO<72.2 AUU/L group. Conclusions MPO may be a powerful predictor of adverse outcome in patients with ACS.(J Geriatr Cardiol 2007;4:209-212)Objective To study whether myeloperoxidase (MPO) can provide prognostic information in patients with acute coronary syndromes (ACS). Methods The study population consisted of 274 consecutive patients with ACS. All patients underwent coronary angiography which showed significant coronary artery disease and blood samples were collected at admission. Follow-ups were scheduled at 1, 3, and 6 months.The end point included cardiac death, acute myocardial infarction (MI), percutaneous or surgical revascularization. Results Patients with elevated MPO serum levels (MPO ≥ 72.2 AUU/L) were more likely to have diabetics and had a history of coronary events. Kaplan-Meier event rate curves with accumulative incidence of end point at 6-month follow-up in the MPO ≥ 72.2 AUU/L group was significantly higher than in MPO<72.2 AUU/L group. Conclusions MPO may be a powerful predictor of adverse outcome in patients with ACS.(J Geriatr Cardiol 2007;4:209-212)

关 键 词：MYELOPEROXIDASE ACUTE CORONARY SYNDROMES 

分 类 号：R[医药卫生]